Capricor Therapeutics Inc (NASDAQ:CAPR) price target lowered to $3.50 by HC Wainwright

Analyst Ratings For Capricor Therapeutics Inc (NASDAQ:CAPR)

Story continues below

Today, HC Wainwright lowered its price target on Capricor Therapeutics Inc (NASDAQ:CAPR) to $3.50 per share.

There are 1 Hold Ratings, 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Capricor Therapeutics Inc (NASDAQ:CAPR) is Buy with a consensus target price of $3.75 per share, a potential 861.54% upside.

Some recent analyst ratings include

  • 12/26/2018-Capricor Therapeutics Inc (NASDAQ:CAPR) gets downgraded to Hold by Maxim Group
  • 7/22/2017-Capricor Therapeutics Inc (NASDAQ:CAPR) had its Buy rating reiterated by Rodman & Renshaw with a $2.15 price target
  • On 5/9/2017 Louis Manzo, Director, bought 10,000 with an average share price of $3.10 per share and the total transaction amounting to $31,000.00.
  • On 5/9/2017 Sinai Medical Center Cedars, Major Shareholder, bought 1,145,161 with an average share price of $3.10 per share and the total transaction amounting to $3,549,999.10.
  • On 9/21/2016 Sinai Medical Center Cedars, Major Shareholder, bought 312,500 with an average share price of $3.20 per share and the total transaction amounting to $1,000,000.00.
  • On 3/16/2016 Anthony Bergmann, VP, bought 2,030 with an average share price of $2.40 per share and the total transaction amounting to $4,872.00.
  • On 3/16/2016 Karen Krasney, EVP, bought 4,060 with an average share price of $2.40 per share and the total transaction amounting to $9,744.00.
  • On 3/16/2016 Leland Gershell, CFO, bought 2,100 with an average share price of $2.40 per share and the total transaction amounting to $5,040.00.
  • On 3/16/2016 Linda Marban, CEO, bought 10,152 with an average share price of $2.40 per share and the total transaction amounting to $24,364.80.

About Capricor Therapeutics Inc (NASDAQ:CAPR)
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Recent Trading Activity for Capricor Therapeutics Inc (NASDAQ:CAPR)
Shares of Capricor Therapeutics Inc closed the previous trading session at 0,39 +0,020 5,38 % with 155836 shares trading hands.

An ad to help with our costs